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I. INTRODUCTION
Enacted twenty years ago, the Hatch-Waxman Amendments'
sought to balance the two competing policy interests of (1) inducing
pioneering research and development of new drugs, and (2) enabling
competitors to bring low-cost generic copies of those drugs to
market.2 The increasing costs of drug development and public
concerns over consumer drug prices have resulted in a renewed focus
on the desired balance between these competing policy objectives.
A. Overview of Hatch- Waxman
1. Pre-Hatch-Waxman
The regulatory framework of the drug approval process before
the Hatch-Waxman Amendments created a number of obstacles, both
for brand-name and generic pharmaceuticals. Notwithstanding the
substantial time and expense of drug discovery and development,
brand-name pharmaceutical companies often had the effective terms
of their patents shortened due to issuance of the patents before FDA
approval of the corresponding drugs and the time required for the
FDA to ensure the safety and efficacy of the brand-name drug.
3
Generic pharmaceutical companies also faced hurdles, such as the
requirement to perform their own safety and efficacy studies.4 In
addition, a generic company could not begin the required FDA
approval process until after patents on the relevant brand-name
product had expired, since to begin earlier would typically have
infringed the patents of the brand-name company. 5 As a result, by
1984 there were approximately 150 brand-name drugs whose patents
had expired but for which there was no generic equivalent.6
1. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-
417, 98 Stat. 1585 (codified as 21 U.S.C. §§ 355, 360cc, and 35 U.S.C. §§ 156, 271, 282 (2000)
(the "Hatch-Waxman Amendments" to the Food, Drug and Cosmetic Act ("FDCA") and to Title
35 of the U.S. Code relating to patents)).
2. Andrx Pharms., Inc. v. Biovail Corp., 276 F.3d 1368, 1371 (Fed. Cir. 2002).
3. See Unimed, Inc. v. Quigg, 888 F.2d 826, 829 (Fed. Cir. 1989) (noting that the intent
of the Hatch-Waxman Amendments was to "ameliorate the loss incurred when patent terms tick
away while the patented product is awaiting regulatory approval").
4. Although the FDA established a policy of permitting the approval of a generic
equivalent to a safe and effective pre-1962 brand-name drug, such generic approval procedure
did not apply to drugs approved after 1962. See H.R. REP. No. 98-857, pt. I, at 16 (1984),
reprinted in 1984 U.S.C.C.A.N. 2647, 2649.
5. See, e.g., Roche Prods., Inc. v. Bolar Pharm. Co., 733 F.2d 858 (Fed. Cir. 1984).
6. H.R. REP. No. 98-857, pt. I, at 17, reprinted in 1984 U.S.C.C.A.N. 2650.
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2. Hatch-Waxman Amendments
The Hatch-Waxman Amendments provided brand-name
pharmaceutical companies with the opportunity to extend the term of
a patent in certain circumstances, thereby restoring patent protection
as compensation for the time used to obtain FDA approval.7 Generic
drug companies were also provided substantial relief from the
approval time delays in two ways. First, generic companies were
allowed to rely on the innovators' safety and efficacy data and merely
demonstrate that their generic drug was "bioequivalent" to the
relevant brand-name product.s  Second, the patent statute was
amended to clarify that it was not an act of infringement to make, use,
or sell a patented invention "solely for uses reasonably related to the
development and submission of information" to the FDA.9
3. Summary of FDA Approval Process10
A pharmaceutical company seeking to manufacture a new drug
must file a New Drug Application ("NDA") for consideration by the
FDA." Preparing an NDA is a time-intensive and costly process
since it must contain, among other things, detailed clinical studies of
the drug's safety and efficacy, as well as a list of patents that claim
the drug.' 2 If the FDA approves the NDA, it publishes a listing of the
drug and patents on the drug's approved aspects in Approved Drug
Products with Therapeutic Equivalence Evaluations, referred to as the
"Orange Book.'
' 3
7. 35 U.S.C. § 156 (2000); see also Merck & Co. v. Kessler, 80 F.3d 1543 (Fed. Cir.
1996) (discussing § 156 as it relates to the Uruguay Round Agreements Act).
8. 21 U.S.C. § 355(j)(2)(A)(iv) (2000). In general, bioequivalence means that the rate
and extent of absorption of the generic drug is not significantly different from the rate and extent
of absorption of the pioneer drug when administered at the same dosage. Id. § 355(j)(8)(B).
9. 35 U.S.C. § 271(e)(1) (2000).
10. The framework governing the approval of pioneering and generic drugs has been
outlined in several recent opinions of the Federal Circuit. See, e.g., Apotex, Inc. v. Thompson,
347 F.3d 1335 (Fed. Cir. 2003); Allergan, Inc. v. Alcon Labs., Inc., 324 F.3d 1322 (Fed. Cir.
2003); Andrx Pharms., Inc. v. Biovail Corp., 276 F.3d 1368 (Fed. Cir. 2002); and Mylan
Pharms., Inc. v. Thompson, 268 F.3d 1323 (Fed. Cir. 2001). See also Eli Lilly & Co. v.
Medtronic, Inc., 496 U.S. 661 (1990).
11. 21 U.S.C. § 355 (a), (b) (2000), amended by the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003, Pub. L. No. 108-173, 117 Stat. 2066 ("Medicare
Act of 2003").
12. Id. § 355 (b)(1). The statute provides for listing only if: (1) the patent "claims the
drug.., or... a method of using such drug" and (2) the patent is one "with respect to which a
claim of patent infringement could reasonably be asserted if a person not licensed by the owner
engaged in the manufacture, use, or sale of the drug." Id.
13. Id. § 355(b)(1), (j)(7)(A)(iii).
2004] HATCH-WAXMAN-PATENTED V. GENERIC DRUGS 699
A company seeking approval of a generic drug may file an
Abbreviated New Drug Application ("ANDA"). 14  In addition to
containing sufficient information to demonstrate that the generic drug
is "bioequivalent" to the relevant brand-name product, the ANDA
process also requires a certification regarding each patent listed in the
Orange Book that relates to the relevant NDA product for which the
applicant is seeking to make a generic version.' 5  In particular, the
ANDA applicant must certify that: (I) no such patent information has
been submitted to the FDA; (II) the patent has expired; (III) the patent
is set to expire on a certain date; or (IV) such patent is invalid or will
not be infringed by the manufacture, use, or sale of the new generic
drug for which the ANDA is submitted.
16
When an ANDA applicant makes a paragraph IV certification,
two additional provisions of the Hatch-Waxman Amendments are
implicated. The first is the automatic "30-month stay" protection
afforded brand-name companies. 17  When an ANDA contains a
paragraph IV certification, the ANDA applicant must give notice to
the patentee and NDA holder, providing a detailed basis for its belief
that the patent is invalid or will not be infringed. 18 The patentee is
then given 45 days to sue the ANDA applicant for infringement.' 9 If
the patentee does not file suit, the ANDA application may be
approved, provided other regulatory requirements (such as
bioequivalence) are satisfied. 20 If the patentee files suit within the 45-
day period, the FDA may not approve the ANDA until the expiration
of the 30-month period beginning on the date of receipt of notice.
21
However, if before the expiration of such period the district court
decides that the patent is invalid or not infringed, the approval will be
14. Id. § 355(). Certain other drug applications, known as 505(b)(2) applications,
include provisions similar to those implicated by the filing of an ANDA.
15. Id. § 355(j)(2)(A)(vii).
16. 21 U.S.C. § 355(j)(2)(A)(vii). These are commonly referred to as paragraph I, 11, Ill
and IV certifications. If one of the listed patents is a method-of-use patent which does not claim
a use for which the applicant is seeking approval, the applicant must make a statement to that
effect (a "section viii statement"). Id. § 355(j)(2)(A)(viii).
17. Id. § 3550)(5)(B)(iii).
18. Id. § 355(j)(2)(B). The FDA regulations state that the notice should include a detailed
statement of the factual and legal basis for the applicant's opinion that the patent is not valid,
unenforceable, or will not be infringed. 21 C.F.R. §§ 314.52(c)(6), 314.95(c)(6) (West,
WESTLAW through Mar. 12, 2004).
19. 21 U.S.C. § 355(j)(5)(B)(iii) (2000), amended by the Medicare Act of 2003.
20. See id. § 355(j)(4).
21. Id. § 355(j)(5)(B)(iii). The statute further provides for "such shorter or longer period
as the court may order because either party to the action failed to reasonably cooperate in
expediting the action." Id.
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made effective on the date of the judgment, settlement order or
consent decree reflecting the court's decision.2 2 If the district court
decides the patent has been infringed and the judgment of the district
court is appealed, the approval shall be effective on the date the
appellate court decides the patent is invalid or not infringed, or the
date of a settlement order or consent decree signed by the appellate
court stating that the patent is invalid or not infringed.23 If the court
decides that the patent has been infringed, and the judgment is not
appealed or is affirmed, the approval is effective on the date the
district court orders pursuant to 3 5 U.S.C. § 271 (e)(4)(A).24
The second provision implicated by a paragraph IV certification
is the 180-day period of exclusivity. 25 The first generic applicant to
file an ANDA containing a paragraph IV certification is eligible for
180-days of market exclusivity, during which the FDA may not
approve subsequent ANDAs for the same drug product.26 This
exclusivity period increases the economic incentives for a generic
company to be the first to file an ANDA containing a paragraph IV
certification, as well as an incentive for generic companies to litigate
patents that may be invalid or not infringed.27
B. FTC Recommendations
In July 2002, the Federal Trade Commission published the final
results of its industry-wide study focused on certain aspects of generic
drug competition under the Hatch-Waxman Amendments.28 The
automatic 30-month stay and 180-day period of exclusivity implicated
by a generic ANDA applicant making a paragraph IV certification




24. Id. This section provides that "the court shall order the effective date of any
approval ... to be a date which is not earlier than the date of the expiration of the patent which
has been infringed." 35 U.S.C. § 271(e)(4)(A) (2000).
25. 21 U.S.C. § 355(j)(5)(B)(iv) (2000), amended by the Medicare Act of 2003.
26. Id. The 180-day exclusivity period is triggered by the first commercial marketing of
the generic product. Id. Sometimes ANDA applicants share the 180-day period. See, e.g.,
Apotex, Inc. v. Thompson, 347 F.3d 1335, 1341 (Fed. Cir. 2003).
27. See TorPharm, Inc. v. Thompson, 260 F. Supp. 2d 69, 72-73 (D.D.C. 2003).
28. FEDERAL TRADE COMMISSION, GENERIC DRUG ENTRY PRIOR TO PATENT
EXPIRATION: AN FTC STUDY (July 2002), available at
http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf [hereinafter FTC REPORT].
29. See id. at 6-8, 39-63.
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Recommendation 1: Permit only one automatic 30-month stay
per drug product per ANDA to resolve infringement disputes
over patents listed in the Orange Book prior to the filing date
of the generic applicant's ANDA.
30
The FTC cited several reasons for this recommendation. It noted
that one 30-month period historically has approximated the time
needed for FDA review and approval of the generic's ANDA.31
Further, the data uncovered by the FTC indicated that court decisions
in ANDA-related patent litigation typically are not reached much
earlier than 30 months from notice of the generic's ANDA.32 Against
these findings, the FTC noted that the history of multiple 30-month
stays caused by the filing of later-issued patents appeared
"problematic., 33 The FTC further noted that multiple 30-month stays
prevented FDA approval of the generic applicants' ANDAs for 4 to
40 months beyond the initial 30-month period.34
Regarding this recommendation, the FTC also surmised that
permitting only one 30-month stay per drug product per ANDA
should eliminate most of the potential for improper Orange Book
listings to generate unwarranted 30-month stays.35 The FTC made
some suggestions in this regard, including clarification of the FDA
listing requirements and permitting a generic applicant to raise
listability issues as a counterclaim in the context of patent
infringement litigation initiated by the brand-name company.36
Recommendation 2: Pass legislation to require brand-name
companies and first generic applicants to provide copies of
certain agreements to the Federal Trade Commission.
37
In making this recommendation, the FTC noted that generic
applicants prevailed in nearly 75% of the patent litigation ultimately
resolved by a court decision.38 Further, the data indicated that, upon
receiving FDA approval, first generic applicants that were not sued
began commercial marketing in a timely manner, thereby triggering
30. FTC REPORT, supra note 28, at ii, 39.
31. Id. at iv.
32. Id.
33. Id. The FTC noted that of the eight drug products involving later-issued patents
identified in the FTC Report, all four that had been adjudicated resulted in the later-issued patent
being found invalid or not infringed. Id. at iii-iv, 40.
34. FTC REPORT, supra note 28, at iii, 40.
35. Id. atv.
36. Id. See also infra Parts ILA, III.D.
37. FTC REPORT, supra note 28, at vi, 40
38. Id. at viii.
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the running of the 180 days and allowing FDA approval of any
subsequent eligible generic applicant once the 180-day exclusivity
period had run.39 The FTC noted, however, that antitrust issues may
arise when brand-name companies and first generic applicants reach
agreements that have the potential to "park" the first generic
applicant's 180-day exclusivity for some period of time. 40 The FTC
stated that 14 of the 20 final settlement agreements obtained through
its study had this potential as of the time they were executed. 41 Thus,
the FTC concluded that notification of such agreements to the FTC
and the U.S. Department of Justice was warranted.4 2
II. REGULATORY DEVELOPMENTS
A. FDA Regulations
In response to concerns raised in the FTC Report and elsewhere,
the FDA amended its regulations (21 C.F.R. pt. 314) effective August
18, 2003. 43 The new regulations permit only one 30-month stay per
ANDA and clarify the patent submission and listing requirements for
new drug applications.4 4 In particular, the final rule:
" Allows a full opportunity for only one 30-month stay per
ANDA or 505(b)(2) application;
* Prohibits the submission of patents claiming packaging,
intermediates, or metabolites;
" Requires the submission of certain patents claiming a
different polymorphic form of the active ingredient
described in the NDA;
* Adds a requirement that for submission of polymorph
patents the NDA holder must have test data
demonstrating that a drug product containing the
39. Id.
40. Id. at viii, 34.
41. Id.
42. Id. at viii. See also infra Part III.B.
43. Applications for FDA Approval to Market a New Drug: Patent Submission and
Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New
Drug Applications Certifying That a Patent Claiming a Drug Is Invalid or Will Not Be
Infringed, 68 Fed. Reg. 36,676 (Jun. 18, 2003) (to be codified at 21 C.F.R. pt. 314) [hereinafter
FDA Approval Applications]. The compliance date for submission of information on
polymorph patents is Dec. 18, 2003. Id. Drug substances that are the same active ingredient,
but in different physical forms, are often called "polymorphs." Id. at 36,678.
44. Id. at 36,677-78.
[Vol. 20
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polymorph will perform the same as the drug product
described in the NDA;
" Makes changes to the patent information required to be
submitted and provides declaration forms for submitting
that information to the FDA, both with the NDA and
after NDA approval; and
" Does not require claim-by-claim listing on the
declaration form except for method-of-use patents
45
claiming approved methods of use.
1. One 30-Month Stay Per ANDA
Acknowledging a "change in position," the FDA amended its
regulations on the notice required by an applicant filing a paragraph
IV certification by eliminating that requirement when the application
already contains a paragraph IV certification.4 The amendment was
construed by the FDA as allowing "a full opportunity for only one 30-
month stay per ANDA or 505(b)(2) application., 47
In amending its regulations, the FDA stated that "[m]ultiple 30-
month stays increase the delay in approval of generic drugs and result
in increased costs to consumers. 4 8  The FDA explained in some
detail that "the act is ambiguous on this issue of multiple 30-month
stays" and that "the statutory language may plausibly be read in
different ways." 49  It nevertheless concluded that its "pre-existing
regulations permitting multiple 30-month stays have led to protracted
delays in generic drug approvals and, therefore, need to be
changed.5°
2. Patent Listing Regulations
The new regulations seek to clarify the types of patents for
which information must be submitted and for which information must
not be submitted.5' Patents for which information must be submitted
include drug substance (active ingredient) patents, drug product
45. Id. at 36,677.
46. Id. at 36,693. The Medicare Act of 2003, discussed infra Part III, essentially reversed
this regulation by requiring notice "regardless of whether the applicant has already given
notice." Medicare Act of 2003, supra note 11, § I 101(a)(l).
47. FDA Approval Applications, supra note 43, at 36,677.
48. Id. at 36,690.
49. Id. at 36,693.
50. Id. at 36,694.
51. 21 C.F.R. § 314.53(b) (West, WESTLAW through Mar. 12, 2004).
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(formulation and composition) patents, and method-of-use patents.5 2
Information on process patents, and patents claiming packaging,
metabolites, and intermediates, must not be submitted to the FDA.53
The new regulations raise particular issues about polymorphs and
method-of-use patents.
a. Polymorphs
For patents that claim a polymorph that is the same as the active
ingredient described in the approved or pending application, the new
regulations require the applicant to certify in the declaration forms
that it has certain test data demonstrating that a drug product
containing the polymorph will perform the same as the drug product
described in the new drug application.5 4 The regulations further
specify the nature of the test data required to support the statement in
the declaration.5 5  The FDA noted that the test-data certification
requirement replaces the test data required of ANDA applicants to
demonstrate that the drug product containing the polymorph described
in the ANDA will perform the same as the drug product described in
the NDA.
5 6
b. Method-of- Use Patents
For patents that claim a method of use, the new regulations
require the applicant to submit information only on those patents that
claim indications or other conditions of use described in the pending
or approved application.57 Further, the applicant must separately
identify each pending or approved method of use and related patent
claim.58 For approved applications, the applicant must identify with
specificity the section of the approved labeling that corresponds to the
method of use claimed by the patent submitted.59
The FDA cited the recent Federal Circuit opinions in Warner-
Lambert and Allergan, both discussed below, as being consistent with
its position that method-of-use patents that do not claim an FDA
52. Id. § 314.53(b)(1).
53. Id.
54. Id.
55. Id. § 314.53(b)(2).
56. FDA Approval Applications, supra note 43, at 36,679.
57. 21 C.F.R. § 314.53(b)(1).
58. Id.
59. Id.
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approved use must not be submitted for listing in the Orange Book.6 °
The FDA's requirement that an applicant separately identify each
pending or approved method of use and related patent claim is tied to
the "section viii statement" whereby an ANDA or 505(b)(2) applicant
may avoid certifying to a patent by stating that it is not seeking
approval for the use claimed in the listed patent.61 The FDA believed
it was necessary that NDA holders submit more specific information
on the approved methods of use protected by a submitted patent to
effectively implement the certification and section viii statement
provisions.62
B. FTC Enforcement
The FTC has continued to exercise its enforcement authority in
matters related to competition in the pharmaceutical industry.63
1. Bristol-Myers Squibb
On April 14, 2003, the FTC issued its Decision and Order
against Bristol-Myers Squibb ("BMS") regarding anticancer drugs
Taxol and Platinol and the antianxiety agent BuSpar.64  The
Complaint giving rise to the Consent Order alleged a course of
conduct by BMS that included paying a would-be competitor $72.5
million to abandon its challenge to a BMS patent and stay off the
market until the patent expired, abusing FDA regulations to block
generic entry, making false statements to the FDA in listing patents in
the Orange Book, engaging in inequitable conduct before the PTO,
and filing baseless patent infringement suits. 65
60. Applications for FDA Approval to Market a New Drug: Patent Submission and
Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New
Drug Applications Certifying That a Patent Claiming a Drug Is Invalid or Will Not Be
Infringed, 68 Fed. Reg. at 36,681-82. Warner-Lambert and Allergan are discussed infra Part
IV.B.
61. Id.
62. Id. at 36,682-83.
63. For an overview of FTC activity in the pharmaceutical arena, see FEDERAL TRADE
COMMISSION, FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS (Nov.
8, 2002), available at http://www.ftc.gov/bc/rxupdate02ll08.htm and Joseph J. Simons, Report
from the Bureau of Competition, Address Before the 51 st Annual ABA Antitrust Section Spring
Meeting (Apr. 4, 2003), at
http://www.ftc.gov/speeches/other/030404simonsaba.htm.
64. In re Bristol-Myers Squibb Co., F.T.C. No. C-4076 (Apr. 14, 2003) ("Consent
Order"), available at http://www.ftc.gov/os/caselist/c4076.htm.
65. In re Bristol-Myers Squibb Co. (Apr. 14, 2003) [hereinafter Complaint] and FEDERAL
TRADE COMMISSION, ANALYSIS TO AID PUBLIC COMMENT (Mar. 7, 2003) [hereinafter FTC
ANALYSIS], at http://www.ftc.gov/os/caselist/c4076.htm.
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The FTC identified BuSpar, Taxol, and Platinol, and their
respective generic bioequivalent versions, as three distinct antitrust
markets in which BMS had monopoly power.6 6 Further, a significant
focus of the FTC's Complaint was on the alleged improper listing of
patents in the Orange Book.6 7 The FTC asserted that "the Orange
Book listing scheme is susceptible to opportunistic behavior" 68 and
affirmatively pled in its complaint that BMS's conduct was not
immune from antitrust liability under the Noerr-Pennington
doctrine.69
The Consent Order includes a specific prohibition against the
listing of U.S. Patent No. 6,150,365 (issued November 21, 2000) 70 in
the Orange Book, as well as a general prohibition against Orange
Book listings that are contrary to the statutes and regulations
governing the listings.7 1  Also included in the Consent Order are
certain prohibitions against triggering the 30-month stay of FDA
approval of a generic applicant.72  Finally, the Consent Order
prohibits certain agreements with ANDA filers, including certain
agreements prohibiting the ANDA filer from researching, developing,
manufacturing, marketing and selling certain products,73 certain
agreements restricting relinquishment of the right to the 180-day
exclusivity period, 74 and certain agreements in patent infringement
disputes prohibiting the sale of certain products by the ANDA filer.75
2. Schering-Plough
On December 8, 2003, the FTC issued its Final Order against
Schering-Plough Corporation ("Schering") and Upsher-Smith
Laboratories, Inc. ("Upsher") involving the settlement of patent
66. Complaint, supra note 65, 64, 104, 123.
67. Complaint, supra note 65, 50, 90, 94, 137, 142, 149.
68. FTC ANALYSIS, supra note 65, at 8.
69. Complaint, supra note 65, 132; see Eastern R.R. Presidents Conference v. Noerr
Motor Freight, Inc., 365 U.S. 127 (1961); United Mine Workers v. Pennington, 381 U.S. 657
(1965). See also Organon Inc. v. Mylan Pharms., Inc., 293 F. Supp. 2d 453 (D.N.J. 2003)
(finding that filing a patent for listing in the Orange Book is not "petitioning activity" within the
meaning of the Noerr-Pennington doctrine).
70. Consent Order, F.T.C. No. C-4076, II. U.S. Patent No. 6,150,365 has been the
subject of several reported opinions. See, e.g., In re Buspirone Patent Litig., 185 F. Supp. 2d
363 (S.D.N.Y. 2002); In re Buspirone Patent Litig., 185 F. Supp. 2d 340 (S.D.N.Y. 2002);
Mylan Pharms., Inc. v. Thompson, 268 F.3d 1323 (Fed. Cir. 2001).
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litigation in the context of Hatch-Waxman.76 The Complaint, issued
on March 30, 2001, charged that Schering, Upsher and American
Home Products Corporation ("AHP") violated section 5 of the FTC
Act, 15 U.S.C. § 45, by entering into agreements to delay the entry of
low-cost generic competition to Schering's prescription drug K-Dur
2077 The Commission reversed an Initial Decision dismissing the
Complaint and entered a Final Order, concluding that the agreements
at issue violated section 5 of the FTC Act.78 The Commission applied
the rule-of-reason standard in its analysis, specifically noting the trend
of authority moving in that direction.79
The Final Order provides for prospective relief only.8° It
provides certain prohibitions on final and interim settlement
agreements in the context of Hatch-Waxman patent infringement
litigation.81 It further provides for notification to the FTC prior to
consummation of certain agreements.82
III. LEGISLATIVE DEVELOPMENTS
On December 8, 2003, President Bush signed the Medicare Act
of 2003 into law.83 Among other amendments, the legislation
addresses limits to the 30-month stay provisions, certain agreements
entered into by generic applicants, declaratory judgment actions by
generic applicants, and Orange Book listing remedies.84
A. Limits to 30-Month Stay
The Medicare Act of 2003 amended the provisions of the FDCA
relating to the 30-month stay by stating that the action triggering such
stay is one brought for infringement of the patent that is the subject of
the paragraph IV certification and "for which information was
76. In re Schering-Plough Corporation, F.T.C. No. 9297 (Dec. 8, 2003) ("Final Order"),
available at http://www.ftc.gov/os/adjpro/d9297/index.htm.
77. THOMAS B. LEARY, OPINION OF THE COMMISSION ON IN THE MATTER OF SCHERING-
PLOUGH CORPORATION, ET AL. 2 [hereinafter OPINION OF THE COMMISSION], available at
http://www.fic.gov/os/adjpro/d9297/031218commissionopinion.pdf. Although AHP was
initially named as a Respondent, it agreed to a settlement and a Final Consent Order was
approved Apr. 2002. Id. at 5.
78. Id. at 86.
79. Id. at 12-13, 87. The Commission's Opinion discusses In re Cardizem and Valley
Drug, both discussed infra Part IV.D.
80. OPINION OF THE COMMISSION, supra note 77, at 87; Final Order, supra note 76.
81. Final Order, supra note 76, II, IV.
82. Id. V.
83. Medicare Act of 2003, supra note 11.
84. Id.
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submitted to the Secretary under subsection (b)(1) or (c)(2) before the
date on which the application (excluding an amendment or
supplement to the application), which the Secretary later determines
to be substantially complete, was submitted." 85  Such language
essentially limits the 30-month stay to infringement suits based on
patents listed before the date of submission of the generic drug
application.
86
B. Agreements By Generic Applicants
As noted above, the FTC Report identified potential antitrust
concerns arising from agreements between brand-name and generic
companies.8 7 The Medicare Act of 2003 addresses these concerns by
providing for forfeiture of the 180-day exclusivity if an applicant
submitting a paragraph IV certification has entered into an agreement
with another applicant, or the holder of the NDA or patent owner, in
violation of the antitrust laws.88 In addition, the legislation sets
certain filing requirements for (1) agreements between generic drug
applicants and brand-name drug companies regarding (a) the
manufacture, marketing, or sale of the brand-name or generic drug, or
(b) the 180-day exclusivity period, and (2) agreements between
generic drug applicants regarding the 180-day exclusivity period.89
Each party must file the agreement and certain related agreements
with the Assistant Attorney General and the FTC not later than ten
business days after the date of execution.
90
C. Declaratory Judgment Actions
The Medicare Act of 2003 includes provisions amending the
FDCA and Title 35 to allow a generic applicant to file a declaratory
85. Medicare Act of 2003, supra note 11, § I 101 (a)(2)(A)(ii)(I). Similar amendments are
included for applications pursuant to 21 U.S.C. § 355(b). Id. § 1 101(b)(2)(B)(i).
86. These amendments apply with respect to patent information submitted under
subsection (b)(l) or (c)(2) of section 505 of FDCA on or after August 18, 2003, the effective
date of the FDA regulations discussed supra Part N.A.
87. FTC REPORT, supra note 28, at viii.
88. Medicare Act of 2003, supra note 11, § 1102(a). The legislation contemplates a
decision resulting from a complaint filed by the FTC or the Attorney General. The term
"antitrust laws" includes section 1 of the Clayton Act (15 U.S.C. § 12) and section 5 of the
Federal Trade Commission Act (15 U.S.C. § 45) to the extent that that section applies to unfair
methods of competition. Id.
89. Id. § 1112.
90. Id. §§ 1112-13. Violation includes liability for a civil penalty of up to $11,000 for
each day an entity fails to comply, recoverable in a civil action brought by the United States or
the FTC. Id. § 1115.
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judgment of patent invalidity or noninfringement if the patent owner
or NDA holder does not bring a patent infringement suit on or before
the date that is 45 days after receipt of notice from the generic
applicant.91 Section 271(e) of the Patent Act has also been amended
to clarify that the federal courts shall have subject matter jurisdiction
in such declaratory judgment actions "to the extent consistent with the
Constitution., 92  This language was included to assuage concerns
raised during deliberation of the legislation. The Department of
Justice had argued that a federal court's jurisdiction emanates from
Article III of the Constitution and that Congress cannot expand the
courts' power to hear cases beyond what the Constitution provides.93
Jon W. Dudas, Deputy Director of the USPTO, had also raised a
concern that the proposed statutorily-created right to a declaratory
judgment action could result in unnecessary harassment of patent
owners through litigation and patent uncertainty as a result of such
litigation.
94
D. Orange Book Listing Remedies
The Medicare Act of 2003 amends the FDCA to permit an
applicant to assert a counterclaim requiring the holder of the NDA to
correct or delete the patent information on the ground that the patent
does not claim either the drug for which the application was approved
or an approved method of using the drug.95 The provision only
permits a counterclaim to a patent infringement action, not an
independent cause of action, and does not permit the recovery of
damages from a successful counterclaim.
96
91. Medicare Act of 2003, supra note 11, § I l01(a)(2)(C). If the notice relates to
noninfringement, it must be accompanied by a document providing an offer of confidential
access to the application for the purpose of determining whether an infringement action should
be brought. Id. Similar amendments are included in 21 U.S.C. § 355(c)(3). Id.
§ 110 1(b)(2)(D).
92. Id. § 1101(d); see also the newly created 35 U.S.C. § 271(e)(5).
93. Examining the Senate and House Versions of the "Greater Access to Affordable
Pharmaceuticals Act. " Before the Senate Comm. on the Judiciary, 108th Cong. 12 (Aug. 1,
2003) (statement of Sheldon Bradshaw, Deputy Assistant Attorney General, U.S. Department of
Justice).
94. See id, at 7 (statement of Jon W. Dudas, Deputy Under Secretary of Commerce for
Intellectual Property and Deputy Director of the United States Patent and Trademark Office).
95. Medicare Act of 2003, supra note 11, § 1 101(a)(2)(C)(ii), (b)(2)(D)(ii).
96. Id.
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IV. JUDICIAL DEVELOPMENTS
A. § 271(e)(1) Safe Harbor
In Integra LifeSciences , Ltd. v. Merck KGaA. , the Federal
Circuit considered the scope of the "safe harbor" against patent
infringement defined by 35 U.S.C. § 271(e)(1). Section 271(e)(1)
recites in pertinent part:
It shall not be an act of infringement to make, use, offer to sell, or
sell within the United States or import into the United States a
patented invention ... solely for uses reasonably related to the
development and submission of information under a Federal law
which regulates the manufacture, use, or sale of drugs or veterinary
biological products.
98
The Federal Circuit affirmed the district court's determination
that 35 U.S.C. § 271(e)(1) did not immunize Merck KGaA against
liability for patent infringement. 99 However, the Federal Circuit
reversed and remanded the jury's damage award to Integra of
$15,000,000 as a reasonable royalty. 100
Integra owns several U.S. patents related to a short tri-peptide
segment having the amino acid sequence arginine-glycine-aspartic
acid (the "RGD peptide").'' The RGD peptide promotes cell
adhesion and, in theory, plays a role in wound healing,
biocompatibility of prosthetic devices, and the growth of blood
vessels. 102
Merck entered into an agreement with Scripps to fund the
"necessary experiments to satisfy the biological bases and regulatory
(FDA) requirements for the implementation of clinical trials."'0 3 The
agreement contemplated conducting clinical trials with a drug
candidate within three years.104 According to the agreement, Scripps
scientists conducted experiments directed at evaluating several drug
candidates, explaining the mechanism by which they work,
determining which could be safely tested in humans, and determining
97. 331 F.3d 860 (Fed. Cir. 2003), petition for cert. filed (U.S. Mar. 3, 2004) (No. 03-
1237). Finnegan Henderson represented Merck KGaA.
98. 35 U.S.C. § 271(e)(1) (2000).
99. Integra, 331 F.3d at 862, 868.
100. Id. at 872.
101. Id. at 862.
102. Id. at 862-63.
103. Id. at 863.
104. Id.
[ ol. 20
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the mode of administering the candidate drugs that would produce the
optimum therapeutic effect.0 5  This research resulted in the
identification of a lead candidate for clinical development.
0 6
After license negotiations failed, Integra sued Merck, Scripps,
and the scientist in charge of the research that identified the leading
drug candidate, asserting that the research infringed its patents.
0 7
The defendants answered that the research was protected by the safe
harbor afforded by 35 U.S.C. § 271(e)(1) and that Integra's patents
were invalid. 108
The Federal Circuit framed the question as whether experiments
that do not supply information for submission to the FDA, but rather
identified the best drug candidate to subject to future clinical testing,
are exempt from liability for infringement under § 271(e)(1). 10 9
Stated more broadly, the issue was whether the "safe harbor" reaches
back down the chain of experimentation to embrace the identification
and development of new drugs that will be subject to FDA
approval. 110
After reviewing the legislative history of § 271(e)(1), the
Federal Circuit concluded that the focus of the exemption is the
provision of information to the FDA."' It reasoned that, while the
term "reasonably" permits some activities that are not themselves the
experiments that produce FDA information, the exemption does not
extend to general biomedical research to identify new pharmaceutical
compounds. 1 2 As stated by the court, "[t]he FDA has no interest in





The Federal Circuit agreed with Merck that the damage award
was not supported by substantial evidence. 14 According to the court,
105. Integra LifeSciences I, Ltd. v. Merck KGaA, 331 F.3d 860, 863 (Fed. Cir. 2003),




109. Id. at 865.
110. Id. at 865-66.
111. Integra, 331 F.3d at 866.
112. Id. According to the court, extension of the exemption would, for example, vitiate the
rights of patentees owning biotechnology tool patents. Id. at 867.
113. Id. at 866.
114. Id. at 869.
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the record evidence on a hypothetical license negotiation simply did
not support the jury's damage award.' 15
Judge Newman concurred-in-part and dissented-in-part, focusing
on the common law research exemption and § 271(e)(1).' 16
According to Judge Newman, the Scripps/Merck activities were either
exempt exploratory research or immunized by § 271(e)(1):
It would be strange to create an intervening kind of limbo, between
exploratory research subject to exemption, and the FDA statutory
immunity, where the patent is infringed and the activity can be
prohibited. That would defeat the purposes of both exemptions;
the law does not favor such an illogical outcome. 
1 17
B. § 271(e) (2) and Method-of- Use Patents
In Warner-Lambert Co. v. Apotex Corp., 118 the Federal Circuit
considered, as a matter of first impression, whether it is an act of
infringement under 35 U.S.C. § 271(e)(2)(A) to submit an ANDA
seeking approval to make, use, or sell a drug for an approved use if
any other use of the drug is claimed in a patent, or if it is only an act
of infringement to submit an ANDA seeking approval to make, use,
or sell a drug if the drug or the use for which FDA approval is sought
is claimed in a patent. 119 Section 271(e)(2)(A) provides in pertinent
part as follows:
It shall be an act of infringement to submit ... an application under
section 5050) of the Federal Food, Drug, and Cosmetic Act... for
a drug claimed in a patent or the use of which is claimed in a
patent.., if the purpose of such submission is to obtain approval
under such Act to engage in the commercial manufacture, use, or
sale of a drug ... claimed in a patent or the use of which is claimed
in a patent before the expiration of such patent.120
The Federal Circuit concluded that it is not an act of
infringement to submit an ANDA for approval to market a drug for a
use when neither the drug nor that use is covered by an existing
115. Id. at 872.
116. Integra LifeSciences 1, Ltd. v. Merck KGaA, 331 F.3d 860, 872-78 (Fed. Cir. 2003),
petition for cert. filed (U.S. Mar. 3, 2004) (No. 03-1237).
117. Id. at 877.
118. 316 F.3d 1348 (Fed. Cir. 2003).
119. Warner-Lambert, 316 F. 3d at 1354.
120. 35 U.S.C. § 271(e)(2)(A).
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patent, and the patent at issue is for a use not approved under the
NDA.
121
Warner-Lambert is the owner of several patents related to
gabapentin, a cyclic amino acid compound.122  In 1993, Warner-
Lambert obtained approval of an NDA to market gabapentin for use
in "adjunctive therapy in the treatment of partial seizures with or
without secondary generalization in adults with epilepsy."' 123 Apotex
filed an ANDA seeking approval for the same indication, including a
paragraph IV certification for two patents of Warner-Lambert referred
to as the "monohydrate patent" and the "neurodegenerative method
patent."'124 Notwithstanding Apotex's position in its paragraph IV
notice that the neurodegenerative method patent did not claim a
method of using gabapentin and its derivatives for partial seizure,
Warner-Lambert filed suit, alleging that Apotex's submission of its
ANDA was an act of infringement of that patent under §
271(e)(2)(A). 125
In Warner-Lambert's view, a patent claiming a use of a drug is
infringed by the filing of an ANDA irrespective of whether approval
is sought to market the drug for the patented use. 12 6 After reviewing
the Hatch-Waxman Amendments and their legislative history, the
court concluded that Congress did not intend for it to be an act of
infringement to submit an ANDA for a drug if just any use of that
drug was claimed in a patent and the applicant sought approval of its
ANDA prior to the expiration of that patent. 127 Rather, Congress
intended to limit actions for infringement of method-of-use patents
under § 271(e)(2)(A) to "controlling use patents," or patents that
claim an approved use of a drug. 128 Since Apotex was not submitting
an application to sell a drug for treatment of neurodegenerative
diseases, it was entitled to summary judgment of noninfringement. 129
121. Warner-Lambert, 316 F.3d at 1354-55.
122. Id. at 1351-52.
123. Id. at 1352.
124. Id. In filing its ANDA, Apotex sought approval to market generic gabapentin upon
expiration of Wamer-Lambert's "epilepsy method patent." Id. The claim under the
monohydrate patent was the subject of a summary judgment of noninfringement and not an
issue on appeal. Id. at 1353 n.1.
125. Warner-Lambert, 316 F.3d at 1353.
126. Id. at 1355.
127. Id. at 1358-59.
128. Id. at 1362.
129. Id.
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The Federal Circuit also rejected Wamer-Lambert's assertion of
inducement of infringement under § 271 (b) based on its argument that
gabapentin was being prescribed for off-label uses, including for the
treatment of neurodegenerative diseases.130 The court concluded that,
in the absence of any evidence that Apotex has or will promote or
encourage doctors to infringe the neurodegnerative method patent,
there was no genuine issue of material fact on inducement of
infringement. 131
In Allergan, Inc. v. Alcon Laboratories, Inc.,'32 the Federal
Circuit affirmed the district court's grant of summary judgment of
noninfringement.133 Citing Warner-Lambert,'34 the court held that the
action for induced infringement brought by Allergan was not
cognizable under 35 U.S.C. § 271(e)(2). 135 However, all three judges
expressed their disapproval of Warner-Lambert. 1
36
Allergan obtained FDA approval for the use of brimonidine for
reducing intraocular pressure. 137 That use, as well as brimonidine, is
unpatented and in the public domain. 38  After further research,
Allergan discovered that brimonidine was also effective in treating
patients with neurodegeneration of the optic nerve. 139  Allergan
obtained two patents on the use of brimonidine to treat ocular neural
injuries, and listed both in the Orange Book. 40  Later, Alcon and
Bausch & Lomb filed ANDAs to market generic versions of
brimonidine for use in lowering intraocular pressure. 14l
Allergan filed suit for infringement under 35 U.S.C. § 271(e)(2),
contending that if Alcon and Bausch & Lomb obtained approval for
their ANDAs, they would induce doctors to infringe by prescribing
130. Id. at 1363-64.
131. Warner-Lambert, 316 F.3d at 1364. For more on generic gabapentin, see TorPharm,
Inc. v. Thompson, 260 F. Supp. 2d 69 (D.D.C. 2003) discussed infra Part IV.C.
132. 324 F.3d 1322 (Fed. Cir. 2003), cert. denied, 124 S.Ct. 813 (2003) ("Allergan").
Finnegan Henderson represented Allergan before the Federal Circuit. See also Alcon Labs., Inc.
v. Allergan, Inc., 256 F. Supp. 2d 1080, 1085 (C.D. Cal. 2003) (granting motions for summary
judgment of noninfringement eight days before Allergan was decided, noting that Warner-
Lambert confirmed in the court's mind that its analysis was correct).
133. Allergan, 324 F.3d at 1324.
134. Warner-Lambert Co. v. Apotex. Corp., 316 F.3d 1348 (Fed. Cir. 2003).
135. Allergan, 324 F.3d at 1324.
136. See id. at 1334-46.
137. Id. at 1327.
138. Id.
139. Id.
140. Id. at 1328.
141. Allergan, Inc. v. Alcon Labs., Inc., 324 F.3d 1322, 1328 (Fed. Cir. 2003), cert.
denied, 124 S.Ct. 813 (2003).
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(and patients to infringe by using) brimonidine for neuroprotection. 42
Alcon and Bausch & Lomb denied induced infringement by asserting
that their ANDAs were for a use of the drug that is different from the
use of the drug claimed in the asserted patent.
1 43
The district court granted summary judgment, holding that the
filing of an ANDA does not provide a predicate for a method-of-use
patent holder to sue an ANDA applicant for induced infringement.
144
In addition, the district court found that, since there was yet to be any
third-party infringement, the question of inducing infringement would
be entirely too speculative and run afoul of the case or controversy
requirement of Article III of the Constitution.141
Holding that the case was controlled by Warner-Lambert, the
Federal Circuit affirmed the summary judgment of
noninfringement. 146 However, the court disagreed with the rationale
of the district court, noting that the language of § 271 (e)(2) does not
limit the reach of the statute to direct infringement actions to the
exclusion of actions for induced infringement.1 47 The court further
concluded that, while a § 271(e)(2) induced infringement claim may
be speculative, it is not sufficiently so to contravene the case or
controversy requirement.
1 48
Judge Schall, joined by Judge Clevenger, wrote a concurring
opinion disputing the holding of the Court's precedent in Warner-
Lambert.149 Judge Schall noted that the plain language of § 271 (e)(2)
compels the conclusion that an action for infringement may lie based
on the filing of an ANDA for a drug whose use is patented, even if
approval for the patented use is not sought in the ANDA. 15 ° Writing
separately, Judge Linn stated that the court in Warner-Lambert had
overstepped its bounds in interpreting Congress's intent by making
142. Id. at 1328. The Federal Circuit noted that the FDA does not prohibit doctors from
prescribing a drug for an unapproved use, and it does not prohibit patients from using a drug for
an unapproved use. Id. at 1324 n.1.
143. Id. at 1328.
144. Allergan, Inc. v. Alcon Labs., Inc., 200 F. Supp. 2d 1219, 1230-32 (C.D. Cal. 2002).
145. Id. at 1227, 1231.
146. Allergan, 324 F.3dat 1332-34.
147. Id. at 1331.
148. Id. at 1331-32. The Federal Circuit also rejected Allergan's alternative argument that
§ 271 (e)(2) provides a direct cause of action based simply upon the filing of the ANDA. Id. at
1334 n.9.
149. Id. at 1334.
150. Id. at 1335.
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policy choices that were inconsistent with the plain language of the
statute. 5'
C. Battle of the Generics-TorPharm and Purepac
Entitlement to the 180-day exclusivity period was at issue in
TorPharm v. Thompson' 52 and the related predecessor case Purepac v.
Thompson.153 TorPharm and Purepac had submitted rival ANDAs for
the drug gabapentin, which the FDA had earlier approved for the
treatment of epilepsy. 154 The United States District Court for the
District of Columbia held that Purepac alone was entitled to the 180-
day exclusivity to market generic gabapentin.'55
Warner-Lambert had submitted several patents in connection
with the FDA approval of gabapentin for the treatment of epilepsy.
156
Of particular significance were U.S. Patent No. 4,084,479 ("the '479
patent") for a method of using the drug to treat neurodegenerative
diseases and U.S. Patent No. 6,054,482 ("the '482 patent"), a drug
composition patent, which was submitted to the FDA on April 25,
2000, after Warner-Lambert's approval for gabapentin. 157
In March 1998, Purepac submitted an ANDA to market a generic
version of gabapentin for the treatment of epilepsy. 158  Purepac
submitted a section viii statement on the '479 patent when it
submitted its ANDA and, on May 26, 2000, amended its application
to include a paragraph IV certification for the newly submitted '482
patent. 159  Purepac, however, did not mail its required notice to
Warner-Lambert until June 13, 2000.160 On April 20, 1998,
TorPharm submitted its rival gabapentin ANDA.16 1 On June 13,
2000, TorPharm mailed a section viii statement and paragraph IV
certification for the '479 patent, which were received by the FDA on
151. Allergan, 324 F.3d at 1345-46.
152. 260 F. Supp. 2d 69 (D.D.C. 2003).
153. 238 F. Supp. 2d 191 (D.D.C. 2002).
154. TorPharm, 260 F. Supp. 2d at 74-75.
155. Id. at 86.




160. TorPharm, 260 F. Supp. 2d at 78.
161. Id. at 75.
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June 16.162 TorPharm sent its notice to Warner-Lambert on the same
day (June 13) it mailed its certification to the FDA.163
In Purepac, the district court considered the FDA's decision not
to approve Purepac's ANDAs because they contained section viii
statements regarding the '479 patent.64 The district court ruled in
favor of Purepac, holding that the FDA's decision "impermissibly
disregarded both Wamer-Lambert's and the agency's own
understanding of the coverage claimed by that patent., 165 However,
the district court declined to go further and require the FDA to reject
TorPharm's paragraph IV certification to the '479 patent, stating that
it would leave "this delicate question" for the FDA to resolve in the
first instance. 166 On remand, the FDA gave Purepac the exclusive
right to sell gabapentin free from generic competition for 180 days,
deciding that Purepac had exclusivity with respect to the '482 patent
but that no ANDA applicant was eligible for the 180-day exclusivity
with respect to the '479 patent.
167
TorPharm vigorously objected to the FDA's decision and filed
suit, along with a request for a preliminary injunction, on February
14, 2003.168 TorPharm argued that it was entitled to exclusivity on
the '482 patent because it was the first ANDA applicant to comply
with the statutory mandate that notice shall be provided to the NDA
holder (and patent owner) at the same time that the applicant amends
its application to include a paragraph IV certification. 169  While
Purepac did not provide notice to Wamer-Lambert at the same time it
offered its amended certification to the FDA, the appropriate remedy
determined by the FDA was simply delaying the operative date of the
certification to the date notice was sent. 170 The FDA also determined
that the operative date (assuming notice has been sent) for the filing
of an amended certification is the day the certification is received by
the FDA (i.e., June 16 for the TorPharm certification). 7 ' The district
court found that these decisions by the FDA on the '482 patent were
162. Id. at 75, 78.
163. Id. at 78.
164. Purepac Pharm. Co. v. Thompson, 238 F. Supp. 2d 191, 204 (D.D.C. 2002).
165. Id. at 212.
166. Id. at211.
167. TorPharn, 260 F. Supp. 2d at 76, 78.
168. Id. at 79.
169. Id.
170. Id. at 80.
171. Id. at 81.
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reasonable and affirmed the 180-day exclusivity awarded to Purepac
based on that patent. 1
72
Concerning the '479 patent, the district court stated that the FDA
had two options once TorPharm's paragraph IV certification was
deemed improper in light of Purepac's section viii statement.' 73 It
could have required TorPharm to submit its own section viii statement
to replace the rejected paragraph IV certification or it could have done
as it did and removed the patent from the Orange Book altogether, the
delisting regulation posing no impediment to striking the patent from
the agency's records. 174  The district court concluded that, for
exclusivity purposes, there was no functional difference between
these options, and that either way TorPharm's claim to exclusivity
based on the '479 patent was extinguished.1
75
D. Antitrust Issues-In re Cardizem and Valley Drug
In In re Cardizem,176 the Court of Appeals for the Sixth Circuit
considered the antitrust implications of an agreement by a generic
drug manufacturer (Andrx) to refrain from marketing its generic
version of Cardizem CD after receiving FDA approval in exchange
for quarterly payments of $10 million. 7 7 Plaintiffs, direct and
indirect purchasers of Cardizem CD, alleged that the agreement
between Hoescht Marion Roussel, Inc. ("HMR") (now Aventis
Pharmaceuticals) and Andrx was a violation of federal and state
antitrust laws. 178 The foundation of the plaintiffs' claims was that, but
for the agreement, Andrx would have brought its generic product to
market once it received FDA approval and at a lower price than the
patented Cardizem CD sold by HMR.
179
172. Id. at 86.
173. TorPharm, 260 F. Supp. 2d at 85. The district court noted that the FDA has long
taken the position that paragraph IV certifications and section viii statements are mutually
exclusive. Id. at 83.
174. Id. at 85. Under agency regulations, because the patent had been the subject of a
lawsuit based on a paragraph IV certification, it could be delisted only if no ANDA applicant
was, at the time of delisting, entitled to exclusivity based on that patent. Id. at 82; 21 C.F.R. §
314.94(a)(12)(viii)(B) (West, WESTLAW through Mar. 12, 2004).
175. TorPharm, 260 F. Supp. 2d at 85. TorPharm and Purepac were also cited by the
FDA as supporting its construction of the statute with respect to method-of-use patents. FDA
Approval Applications, supra note 43, at 36,681-82.
176. 332 F.3d 896 (6th Cir. 2003), petition for cert, filed, 72 U.S.LW. 3393 (U.S. Nov. 24,
2003) (No. 03-779).
177. Id. at 899-900.
178. Id. at 900.
179. Id. at 904.
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The agreement arose out of a patent infringement suit by HMR
triggered by Andrx's filing of an ANDA and a paragraph IV
certification with respect to the patents listed as covering Cardizem
CD. 80 The agreement was entered into before the expiration of the
statutory 30-month waiting period.' 8' Upon final approval of the
Andrx ANDA, HMR began making quarterly payments of $10
million to Andrx and Andrx refrained from bringing its generic
product to market. 82 Approximately one year later, the parties settled
the infringement suit and terminated the agreement, and Andrx began
marketing its generic product with its 180-day period of market
exclusivity.'
83
The district court granted the plaintiffs' motion for partial
summary judgment and certified two questions for interlocutory
appeal: (1) whether plaintiffs had properly pled antitrust injury, and
(2) whether the agreement between HMR and Andrx constituted a
restraint of trade that was illegal per se under section 1 of the
Sherman Antitrust Act, 15 U.S.C. § 1, and under the corresponding
state antitrust laws. 184 The Sixth Circuit held that the plaintiffs had
properly pled antitrust injury and concluded that the agreement at
issue was a horizontal market allocation agreement and, as such, per
se illegal under the Sherman Act and corresponding state antitrust
laws. 8
5
In Valley Drug Co. v. Geneva Pharmaceuticals, Inc.,186 the Court
of Appeals for the Eleventh Circuit considered the terms of
agreements similar to the agreement in Cardizem, and reversed and
remanded the district court's conclusion that the agreements at issue
constituted per se violations of the antitrust laws.187 According to the
Eleventh Circuit, an antitrust analysis cannot ignore the scope of the
patent exclusion when the exclusionary power of a patent is
implicated. 188  It respectfully disagreed with the Sixth Circuit's
Cardizem opinion to the extent it suggests that a settlement of patent
180. Id. at 902.
181. Id.
182. Cardizem, 332 F.3d at 903.
183. Id.
184. Id. at 900.
185. Id. The court noted, however, that its holding did not resolve the issues of causation
and damages, both of which would have to be established before the plaintiffs could succeed on
their claim for treble damages under the Clayton Act. Id. at 909.
186. 344 F.3d 1294 (11 th Cir. 2003).
187. Id. at 1306, 1310 n.25.
188. Id. at 1310.
720 SANTA CLARA COMPUTER & HIGH TECH. L.. [Vol. 20
litigation was a per se violation of the antitrust laws merely because it
involves a generic's agreement to delay marketing until resolution of
the patent infringement case in exchange for exit payments.'
89
V. CONCLUSION
The tension between the desired support for pioneering drug
development and the public's demand for low-cost generics will
continue to spur activity in the regulatory, legislative, and judicial
arenas. Such activity will undoubtedly require further clarification
and refinement, through litigation or otherwise. As a result, the
desired balance of the competing policy interests originally sought by
the Hatch-Waxman Amendments will remain in flux for some time.
Stay tuned.
189. Id. at 1311 n.26.
